OP008/#194 P53ABN molecular subtype encompasses a morphologically diverse subset of endometrial cancers and identifies therapeutic opportunities to improve outcomes
A. Jamieson, E. Thompson, J. Huvila, S. Leung, A. Lum, L. Helpman, S. Salvador, J. Irving, K. Grondin, A. Lytwyn, C. Parra-Herran, S. Offman, M. Kinloch, M. Plante, D. Vicus, A. Talhouk, S. Scott, D. Huntsman, C. Gilks, J. Mcalpine
{"title":"OP008/#194 P53ABN molecular subtype encompasses a morphologically diverse subset of endometrial cancers and identifies therapeutic opportunities to improve outcomes","authors":"A. Jamieson, E. Thompson, J. Huvila, S. Leung, A. Lum, L. Helpman, S. Salvador, J. Irving, K. Grondin, A. Lytwyn, C. Parra-Herran, S. Offman, M. Kinloch, M. Plante, D. Vicus, A. Talhouk, S. Scott, D. Huntsman, C. Gilks, J. Mcalpine","doi":"10.1136/ijgc-2021-igcs.25","DOIUrl":null,"url":null,"abstract":"ract (7%), lymphopenia (7%), thrombocytopenia (7%), weight loss (7%), hypokalemia (7%). Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/ 4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months. Conclusions Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"2978 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Featured Posters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ract (7%), lymphopenia (7%), thrombocytopenia (7%), weight loss (7%), hypokalemia (7%). Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/ 4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months. Conclusions Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
